The European Commission has approved upadacitinib (Rinvoq) for the Treatment of Moderately to Severely Active Crohn's Di
Tweet Content
The European Commission has approved upadacitinib (Rinvoq) for the Treatment of Moderately to Severely Active Crohn's Disease https://t.co/Clzca7jU5b https://t.co/nNFGe5fF25
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off